Palisade Bio Inc., a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, has appointed J.D. Finley Chief Executive Officer. Finley has been serving as interim CEO since October 2022. “Since assuming the role of interim CEO, J.D. has demonstrated leadership and operational excellence as we have navigated through a difficult transitional period,” said James Neal, chairman of the Palisade Bio board of directors. “Palisade has never been strong...